ArticleBlood research2026
Primary breast follicular lymphoma without a BCL2 rearrangement: insights into extranodal lymphoma biology.
Article in Blood research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary breast lymphoma is a rare malignancy that accounts for less than 1% of non-Hodgkin lymphomas. Diffuse large B-cell lymphoma is the most common subtype, whereas follicular lymphoma (FL) accounts for only a small proportion of cases. Most FL cases involving the breast represent secondary involvement by systemic disease, and true primary breast FL is uncommon. Molecular characterization of primary breast FL has rarely been reported, and its genetic landscape remains poorly understood. CASE PRESENTATION: We report a case of primary breast FL, grade 3A, in a 55-year-old woman who presented with a palpable breast mass. Core needle biopsy revealed an atypical follicular lymphoid proliferation composed of centrocytes and numerous centroblasts (> 15 cells/high-power field). Immunohistochemistry revealed positivity for CD20, PAX5, CD10, and BCL6, with weak BCL2 expression, and a Ki-67 proliferation index of approximately 30%. Fluorescence in situ hybridization did not detect IGH::BCL2, BCL6, or MYC rearrangements but demonstrated copy-number gains involving BCL2, BCL6, MYC, and IGH. Next-generation sequencing identified biallelic CREBBP mutations and a FOXO1 mutation. Clonality studies confirmed a clonal IGK rearrangement in the breast lesion. Staging work-up with positron emission tomography/computed tomography showed disease confined to the breast (stage IE). The patient was treated with R-CHOP chemotherapy followed by involved-site radiotherapy.
conclusionOur findings support the existence of a subset of extranodal follicular lymphomas lacking an IGH::BCL2 rearrangement and highlight alternative pathways of lymphomagenesis with implications for classification and diagnosis. The identification of biallelic CREBBP mutations and a FOXO1 mutation provides molecular insight into extranodal FL biology, suggesting an overlap with nodal FL while supporting alternative oncogenic pathways in extranodal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.